+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy



A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy



Journal of ImmunoTherapy 11(2): 103-110



Twenty patients with advanced cancer for which there was no effective standard therapy or whose disease was refractory to standard therapy were treated with recombinant macrophage colony-stimulating factor (rM-CSF). The rM-CSF was administered by intravenous bolus infusion for 5 consecutive days every other week for 2 treatment weeks. The doses administered ranged from 30 to 33,000 micrograms/m2/day. There was no intrapatient dose escalation. There were minimal to no systemic side effects seen, except for acute dyspnea noted in three patients. The dyspnea was felt to be related to the rate of infusion and did not recur in one patient given additional rM-CSF at a slower infusion rate. The major hematologic effect seen was a mild decrease in platelet count, which began to recover while the patients continued to receive the rM-CSF. The clearance of rM-CSF was dose dependent. Lower doses resulted in a saturable mechanism felt to represent cellular uptake. Clearance at higher doses demonstrated both a first-order mechanism at high serum rM-CSF concentrations, representing renal clearance, as well as a saturable mechanism at low serum concentrations. The maximum mean serum half-life was reached at dose levels of greater than or equal to 3,690 micrograms/m2 and was in the range of 234-258 min. By this route of administration, rises in absolute monocyte count were slight and seen only at doses of greater than or equal to 450 micrograms/m2 during the second therapy week. The maximum tolerated dose was not reached in this study because of lack of availability of rM-CSF.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039095724

Download citation: RISBibTeXText

PMID: 1571332

DOI: 10.1097/00002371-199202000-00004


Related references

Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. Journal of ImmunoTherapy 12(1): 50-54, 1992

Phase i trial of recombinant monocyte macrophage colony stimulating factor in patients with refractory malignancy. Proceedings of the American Association for Cancer Research Annual Meeting 32: 172, 1991

Phase I Trial of Recombinant Human Macrophage Colony-Stimulating Factor Administered by Continuous Intravenous Infusion in Patients With Metastatic Cancer. Jnci Journal of the National Cancer Institute 86(1): 39-45, 1994

Phase I trial of recombinant human macrophage colony-stimulating factor administer by continuous intravenous infusion in patients with metastatic cancer. Journal of the National Cancer Institute 86(1): 39-44, 1994

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. Journal of the National Cancer Institute 82(8): 697-703, 1990

A phase II trial of recombinant human granulocyte macrophage-colony stimulating factor recombinant human interleukin-4 used as combination therapy for subjects with hormone refractory prostate cancer. Journal of Investigative Medicine 50(2): 166A, 2002

Phase l/ll Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Advanced Malignancy. Acta Haematologica 87(1-2): 22-28, 1992

Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Bulletin du Cancer (Paris) 80(5): 418-430, 1993

Phase i ii study of recombinant human granulocyte macrophage colony stimulating factor in patients with advanced malignancy. Acta Haematologica 87(1-2): 22-28, 1992

Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. Behring Institute Mitteilungen 1988(83): 119-124, 1988

Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. Journal of Clinical Oncology 10(10): 1643-1649, 1992

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase-I/II trial. Onkologie 11(1): 53-55, 1988

Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 78(4): 907-913, 1991

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic Syndromes a Phase-I/Ii Trial. Oncology Research and Treatment 11(1): 53-55, 1988

Recombinant human granulocyte macrophage colony stimulating factor gm csf a phase i trial in neutropenic aids patients. Morisset, R A (Ed ) Ve Conference Internationale Sur Le Sida: Le Defi Scientifique Et Social; V International Conference on Aids: The Scientific And Social Challenge; Montreal, Quebec, Canada, June 4-9, 1262p International Development Research Centre: Ottawa, Ontario, Canada Illus Paper 403, 1989